142 Quantifying prion disease penetrance using large population control cohorts.
http://stm.sciencemag.org/content/8/322/322ra9
141 Effect of Artesunate–Amodiaquine on Mortality Related to Ebola Virus Disease.
http://www.nejm.org/doi/full/10.1056/NEJMoa1504605
140 Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE).
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01159-9/abstract
139 Mass Drug Administration for Scabies Control in a Population with Endemic Disease.
http://www.nejm.org/doi/full/10.1056/NEJMoa1500987
138 A cocktail of humanized anti–pertussis toxin antibodies limits disease in murine and baboon models of whooping cough.
http://stm.sciencemag.org/content/7/316/316ra195
137 Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
http://www.thelancet.com/pb/assets/raw/Lancet/pdfs/S0140673615611175.pdf
136 Asymptomatic humans transmit dengue virus to mosquitoes.
http://www.pnas.org/content/112/47/14688.abstract
135 Accurate estimation of influenza epidemics using Google search data via ARGO.
http://www.pnas.org/content/112/47/14473.abstract
134 Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00725-4/abstract
133 Malignant Transformation of Hymenolepis nana in a Human Host.
http://www.nejm.org/doi/full/10.1056/NEJMoa1505892?query=featured_home
132 Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00349-9/abstract
131 Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00237-8/abstract
130 Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00239-1/abstract
129 Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.
http://www.nejm.org/doi/full/10.1056/NEJMoa1506223
128 Administration of thimerosal-containing vaccines to infant rhesus macaques does not result in autism-like behavior or neuropathology.
http://www.pnas.org/content/112/40/12498
127 The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(15)00154-1/abstract
126 Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(15)00074-2/abstract
125 Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)61140-0/abstract
124 Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.
http://www.nejm.org/doi/full/10.1056/NEJMoa1506223
123 A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
http://www.nejm.org/doi/full/10.1056/NEJMoa1507198
|
